NEWS CENTER

The Chairman of Keyuan Pharmaceutical was invited to attend the Third Global Go‑Global Summit, where they jointly explored new pathways for the pharmaceutical industry’s international expansion.

Publish Time:

2026-06-29

On June 28–29, the third Global Outbound Summit, hosted by the Wu Xiaobo Channel and the Chinese Business Globalization Industry Alliance, was grandly held at Resorts World Sentosa in Singapore. Centered around the theme “Born Global—Going Global for Growth,” the summit aligned with the prevailing trend of profound restructuring in global supply chains and the accelerated globalization of China’s real economy. It brought together more than 1,400 entrepreneurs from home and abroad, leading economists, representatives from top-tier investment firms, and experts from industry think tanks, creating a high‑level platform for dialogue, resource matchmaking, and knowledge sharing to support Chinese companies’ international expansion.

On June 28–29, the third Global Outbound Summit, hosted by the Wu Xiaobo Channel and the Chinese Business Globalization Industry Alliance, was grandly held at Resorts World Sentosa in Singapore. Centered around the theme “Born Global—Going Global for Growth,” the summit aligned with the current era of profound restructuring of global supply chains and the accelerated globalization of China’s real economy. It brought together more than 1,400 entrepreneurs from home and abroad, leading economists, representatives from top-tier investment firms, and experts from industry think tanks, creating a high‑level platform for dialogue, resource matchmaking, and knowledge sharing to support Chinese companies’ international expansion.

Deep participation in the conference to jointly discuss new opportunities in the global industrial restructuring.
Shandong Keyuan Pharmaceutical Co.,Ltd. (301281.SZ) was invited to attend, with Chairman Li Hongfu leading the core team to Singapore for an in-person participation. During the summit, Li Hongfu actively engaged in several key agenda items, including keynote speeches, industry closed-door forums, and global resource matchmaking sessions. Drawing on the company’s more than twenty years of experience in global market implementation, he shared insights and practical strategies on how Chinese pharmaceutical enterprises are transitioning from product export to end-to-end global operations.

Deepen the strategy, shifting from product‑level internationalization to industry‑wide globalization.
As a leading enterprise in a specialized segment of the pharmaceutical industry, Keyuan Pharmaceutical has long been on a steady and far‑reaching path toward internationalization. Leveraging more than two decades of sustained dedication, the company’s business network now spans over twenty countries and regions worldwide. Its core products have successfully obtained official regulatory approvals from major global markets, including the U.S. FDA, the EU’s EDQM, Japan’s PMDA, and South Korea’s MFDS, while establishing a fully compliant, end‑to‑end quality management system and a green, intelligent manufacturing framework. These efforts have laid a robust foundation—covering product quality, regulatory compliance, and supply chain resilience—for deepening its presence in international markets.

During the dedicated discussion session, Li Hongfu systematically outlined Keyuan Pharmaceutical’s newly upgraded global development strategy. He stated that the company’s international expansion is advancing in depth across all fronts, marking a strategic shift from exporting individual products to exporting entire industries and comprehensive solutions. Today, global market competition has long moved beyond simple price-based rivalry; for companies seeking to go overseas, it is no longer sufficient to merely export products. Instead, they must proactively integrate deeply into the target market’s regulatory framework, local industrial ecosystems, and end‑market dynamics, building end‑to‑end solutions that encompass R&D customization, compliance certification, flexible manufacturing, localized supply chains, and long‑term technical services—thereby establishing a sustainable, globally scalable growth model resilient to economic cycles.

Building momentum for long-term growth, empowering China’s pharmaceutical industry to go global.
At this third Global Outbound Summit held in Singapore, Keyuan Pharmaceutical has established a high‑level platform for connecting with global capital, overseas distribution channels, and leading industry think tanks. The event has also provided the company with cutting‑edge insights to assess the new cycle of the global pharmaceutical industry and refine its internationalization strategy, offering valuable guidance for its next phase of overseas market expansion, international collaboration, and localized supply‑chain integration.
Following the summit, the company will systematically review the event’s industry insights and leads for global resource partnerships, and, in light of its own sector-specific strengths, further refine its medium- to long-term internationalization strategy.

Looking ahead, Keyuan Pharmaceutical will leverage its practical experience in international expansion to steadily broaden its global partnership network, actively share its expertise in global market deployment with domestic and international peers, and work together to advance the high‑quality “going global” of China’s pharmaceutical industry. By doing so, it aims to establish a new benchmark for China’s pharmaceutical sector within the global supply chain and contribute to the industry’s sustained, high‑quality growth on the world stage.

None

Keyuan Group Conducts Company-Wide Training on Integrity and Compliance, Strengthening the Pharmaceutical Company’s Integrity Defense Line

None

Keyuan Group Conducts Company-Wide Training on Integrity and Compliance, Strengthening the Pharmaceutical Company’s Integrity Defense Line